Ruediger C. Braun-Dullaeus

Dr. Ruediger C. Braun-Dullaeus

Division of Cardiology, Angiology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Magdeburg, Otto von Guericke-University, Magdeburg, Germany
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2002 in Nature Medicine
Verified
Journal Article
Closed access
VDVictor J. Dzau
Victor J. Dzau
RBRuediger C. Braun-Dullaeus
Ruediger C. Braun-Dullaeus
DSDaniel G. Sedding
Daniel G. Sedding

1 September 2025 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MHMaximilian Jonathan Herzog
Maximilian Jonathan Herzog
PMPatrick Müller
Patrick Müller
KLKatharina Lechner
Katharina Lechner
MSMarvin Stiebler
Marvin Stiebler
PAPhilipp Arndt
Philipp Arndt
RBRuediger C. Braun-Dullaeus
Ruediger C. Braun-Dullaeus
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. The central underlying mechanisms of cardiovascular diseases are vascular aging and associated arterial stiffness. Arterial stiffness is characterized by structural (e.g., tunica media calcification, alterations in vascular smooth muscle cells, and fibrosis) and functional (e.g., loss of Windkessel function, elevated pulse pressure, and development of isolated systolic hypertension) vascular changes that cause microvascular dysfunction and end-organ damage (e.g., heart failure, vascular dementia, hypertensive retinopathy, and chronic kidney disease). Current research indicates that arterial stiffness is an independent risk factor for cardiovascular diseases and represents a potential target for personalized prevention and therapeutic approaches. In this review, we summarize the pathophysiological mechanisms of vascular aging and arterial stiffness, outline the resulting end-organ damage, present different methods for the measurement of arterial stiffness, highlight the potential role of prevention and therapy, and provide future perspectives for arterial stiffness research. The purpose of this review is to provide a state-of-the-art interdisciplinary and translational approach to arterial stiffness, highlighting unique pathophysiological mechanisms (e.g., perivascular adipose tissue, extracellular vesicles), clinical relevance, and future directions.

7 July 1998 in Circulation
Verified
Journal Article
Closed access
RBRuediger C. Braun-Dullaeus
Ruediger C. Braun-Dullaeus
MMMichael J. Mann
Michael J. Mann
VDVictor J. Dzau
Victor J. Dzau
—Entry into and progression of vascular cells through the cell cycle is considered a key event in vascular proliferative diseases. Multiple growth factors and cytokines have been found to regulate vascular cell proliferation. However, the machinery regulating cell cycle represents the “final common pathway” of these signaling cascades and thus provides an attractive therapeutic target for the prevention of vascular proliferative diseases. This review focuses on the current understanding of the regulation of the cell cycle machinery especially as it relates to vascular cell biology and the feasibility of targeting cell cycle for the prevention of restenosis after balloon angioplasty and bypass vein graft disease.

1 April 2005 in Circulation Research
Verified
Journal Article
Closed access
PDF file
DSDaniel G. Sedding
Daniel G. Sedding
JHJennifer Hermsen
Jennifer Hermsen
USUlrike Seay
Ulrike Seay
OEOliver Eickelberg
Oliver Eickelberg
WKWolfgang Kummer
Wolfgang Kummer
RBRuediger C. Braun-Dullaeus
Ruediger C. Braun-Dullaeus
Mechanotransduction represents an integral part of vascular homeostasis and contributes to vascular lesion formation. Previously, we demonstrated a mechanosensitive activation of phosphoinositide 3-kinase (PI3-K)/protein kinase B (Akt) resulting in p27 Kip1 transcriptional downregulation and cell cycle entry of vascular smooth muscle cells (VSMC). In this study, we further elucidated the signaling from outside-in toward PI3-K/Akt in vitro and in an in vivo model of elevated tensile force. When VSMC were subjected to cyclic stretch (0.5 Hz at 125% resting length), PI3-K, Akt, and Src kinases were found activated. Disrupting caveolar structures with β-cyclodextrin or transfection of VSMC with caveolin-1 antisense oligonucleotides (ODN) prevented PI3-K and Akt activation and cell cycle entry. Furthermore, PI3-K and Akt were resistant to activation when Src kinases were inhibited pharmacologically or by overexpression of a kinase-dead c-Src mutant. α V β 3 integrins were identified to colocalize with PI3-K/caveolin-1 complexes, and blockade of α V β 3 integrins prevented Akt activation. The central role of caveolin-1 in mechanotransduction was further examined in an in vivo model of elevated tensile force. Interposition of wild-type (WT) jugular veins into WT carotid arteries resulted in a rapid Akt activation within the veins that was almost abolished when veins of caveolin-1 knockout (KO) mice were used. Furthermore, late neointima formation within the KO veins was significantly reduced. Our study provides evidence that PI3-K/Akt is critically involved in mechanotransduction of VSMC in vitro and within the vasculature in vivo. Furthermore, caveolin-1 is essential for the integrin-mediated activation of PI3-K/Akt.

1 May 2003 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
RPRenate Paddenberg
Renate Paddenberg
BIBarat Ishaq
Barat Ishaq
AGAnna Goldenberg
Anna Goldenberg
PFPetra Faulhammer
Petra Faulhammer
FRFrank Rose
Frank Rose
WKWolfgang Kummer
Wolfgang Kummer
In the pulmonary vasculature, the mechanisms responsible for oxygen sensing and the initiation of hypoxia-induced vasoconstriction and vascular remodeling are still unclear. Nitric oxide (NO) and reactive oxygen species (ROS) are discussed as early mediators of the hypoxic response. Here, we describe a quantitative analysis of NO- and ROS-producing cells within the vascular walls of murine lung sections cultured at normoxia or hypoxia. Whereas the number of NO-producing cells was not changed by hypoxia, the number of ROS-generating cells was significantly increased. Addition of specific inhibitors revealed that mitochondria were the source of ROS. The participation of the individual mitochondrial complexes differed in normoxic and hypoxic ROS generation. Whereas normoxic ROS production required complexes I and III, hypoxic ROS generation additionally demanded complex II. Histochemically demonstrable succinate dehydrogenase activity of complex II in the arterial wall decreased during hypoxia. Inhibition of the reversed enzymatic reaction, i.e., fumarate reductase, by application of succinate, specifically abolished hypoxic, but not normoxic, ROS generation. Thus complex II plays an essential role in hypoxic ROS production. Presumably, its catalytic activity switches from succinate dehydrogenase to fumarate reductase at reduced oxygen tension, thereby modulating the directionality of the electron flow.

1 June 2012 in American Heart Journal
Verified
Journal Article
Closed access
HTHolger Thiele
Holger Thiele
GSGerhard Schuler
Gerhard Schuler
FNFranz-Josef Neumann
Franz-Josef Neumann
JHJörg Hausleiter
Jörg Hausleiter
HOHans-Georg Olbrich
Hans-Georg Olbrich
UZUwe Zeymer
Uwe Zeymer